Eli Lilly and Novo Nordisk are leading efforts to curb the sale of compounded GLP-1 medications. Lilly has issued hundreds of cease-and-desist letters to entities selling compounded tirzepatide, following the end of its FDA-declared shortage. Novo Nordisk, whose semaglutide drugs remain in shortage, is taking a different approach. The company published a peer-reviewed study in Pharmaceutical Research, highlighting quality concerns in compounded semaglutide samples, including lower-than-claimed strength and banned ingredients. These actions signal a broader industry pushback against compounders who entered the market during drug shortages. Wired adds: With mounting evidence that GLP-1s like tirzepatide are an effective treatment for other ailments beyond obesity and diabetes -- including addiction and Parkinson's disease -- demand is only expected to increase. It remains to be seen whether the pharmaceutical companies will be able to keep pace with the demand or if the meds will go back into shortage and compounders will be able to bound back into the market.

The rapid increases in life expectancy seen in the 20th century have slowed significantly, according to a new analysis published in the journal Nature. The Guardian reports: According to the study, children born recently in regions with the oldest people are far from likely to become centenarians. At best, the researchers predict 15% of females and 5% of males in the oldest-living areas will reach 100 this century. "If you're planning for retirement, it's probably not a good idea to assume you're going to make it to 100," said Jay Olshansky, professor of epidemiology and biostatistics at the University of Illinois at Chicago. "You'd probably have to work for at least 10 years longer than you'd think. And you want to enjoy the last phase of your life, you don't necessarily want to spend it working to save for time you're not going to experience."

Advances in public health and medicine sparked a longevity revolution in the 20th century. In the previous 2,000 years, life expectancy crept up, on average, one year every century or two. In the 20th century, average life expectancy rocketed, with people gaining an extra three years every decade. For the latest study, Olshansky delved into national statistics from the US and nine regions with the highest life expectancies, focusing on 1990 to 2019, before the Covid pandemic struck. The data from Hong Kong, Japan, South Korea, Australia, France, Italy, Switzerland, Sweden, and Spain showed that rises in life expectancy had slowed dramatically. In the US, life expectancy fell [T]he researchers describe how on average, life expectancy in the longest-living regions rose only 6.5 years between 1990 and 2019. They predict that girls born recently in the regions have only a 5.3% chance of reaching 100 years old, while boys have a 1.8% chance.

"In the modern era we have, through public health and medicine, manufactured decades of life that otherwise would not exist," Olshansky said. "These gains must slow down. The longevity game we're playing today is different to the longevity game we played a century ago when we were saving infants and children and women of child-bearing age and the gains in life expectancy were large. Now the gains are small because we're saving people in their 60s, 70s, 80s, and 90s." Olshansky said it would take radical new treatments that slow ageing, the greatest risk factor for many diseases, to achieve another longevity revolution. Research in the field is afoot with a dozen or so drugs shown to increase the lifespan of mice.

Three scientists won the 2024 Nobel Prize in Chemistry on Wednesday for their groundbreaking work in predicting and designing protein structures, the Royal Swedish Academy of Sciences announced in Stockholm. David Baker of the University of Washington shares the prize with Demis Hassabis and John Jumper of Google DeepMind. Baker pioneered the creation of novel proteins, while Hassabis and Jumper developed AlphaFold, an AI model that predicts protein structures from amino acid sequences.

The laureates will split the 11 million Swedish kronor ($1 million) award for their contributions to computational protein design and structure prediction. Baker's team has produced proteins with applications in medicine and materials science since his initial breakthrough in 2003. Hassabis and Jumper's AlphaFold, announced in 2020, has predicted structures for nearly all 200 million known proteins. "We glimpsed at the beginning that it might be possible to create a whole new world of proteins that address a lot of the problems faced by humans in the 21st century," Baker said at a press briefing.

"Now it's becoming possible," Heiner Linke, chair of the Nobel chemistry committee, called the discoveries "spectacular," noting they fulfilled a 50-year-old dream of predicting protein structures from amino acid sequences. The breakthroughs have wide-ranging implications, from understanding antibiotic resistance to developing enzymes that decompose plastic. Over 2 million researchers worldwide have already utilized AlphaFold in various applications.

American scientists Victor Ambros and Gary Ruvkun won the Nobel Prize in Physiology or Medicine on Monday for discovering microRNA, tiny molecules that regulate gene expression. Their groundbreaking work in the 1990s revealed a new layer of genetic control, opening fresh avenues for understanding human development and disease.

Ambros first identified microRNA in 1993, while Ruvkun later found similar molecules in humans and other species. These RNA fragments, about 100 times smaller than typical messenger RNA, can silence genes and fine-tune protein production. The discovery has spurred research into potential treatments for cancer, heart disease, and neurological disorders. Several biotechnology companies are now developing drugs that target or mimic microRNAs.

Concern over potential human-to-human transmission of bird flu has risen after six Missouri healthcare workers developed mild respiratory symptoms following contact with a patient infected with H5N1. The CDC reports only the original patient has tested positive for the virus. Scientists are ramping up efforts to develop mRNA vaccines against H5N1, with researchers at the University of Pennsylvania and major pharmaceutical companies like Moderna, Pfizer, and GSK leading the charge. While mRNA technology offers rapid vaccine production, clinical trials have shown mixed results, particularly against influenza B strains. Wired adds: [...] Traditionally, flu vaccines contain inactivated viruses that are grown in hens' eggs. This works reasonably well, but it takes a long time to make such jabs, which means health authorities have to publish their predictions about which strains of flu will be circulating during the upcoming winter well in advance. If you could manufacture vaccines more quickly, you could make more accurate predictions nearer to flu season.

Not only that, researchers hope that a single mRNA shot could one day target 20 or more strains of flu at once, relieving the need for some of this guesswork. Scher's colleagues are working on such a "universal" flu vaccine. With clinical trials ongoing, it's still early days. Sheena Cruickshank, an immunologist at the University of Manchester, has watched reports about emerging mRNA flu jabs with interest but says that questions remain. "We don't yet know how long-lasting the immunity they produce is," she says. Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota, concurs, though he notes that all flu jabs, regardless of how they are made, have a waning immunity problem -- your protection could decline by around 10 percent every month following injection.

Researchers have discovered that a popular food dye used in Cheetos "alters the optical qualities of skin, allowing light to pass through (Source paywalled; alternative source)," according to the Wall Street Journal. Larger doses of the dye used on humans could make searching veins for blood draw easier. From a report: Tartrazine, the yellowing agent for the "dangerously cheesy" snack, was tested on the stomachs and heads of mice -- with surprising results. Researchers were even able to see muscle pulsations and blood vessels in their brains, the Wall Street Journal reported.

How does this ultimate magic trick work? It has to do with how cells are comprised of membranes that hold fats in a watery style, the outlet stated. The fats and water manage light differently. In this case, when the dye is applied, it causes light to pass through when it hits their cells. Thus, ta-da! the transparent opacity of invisible mice skin. The findings have been published in the journal Science.

Thursday America's Food and Drug Administration approved Cobenfy, "the first new drug to treat people with schizophrenia in more than 30 years," reports ABC News: Most schizophrenia medications, broadly known as antipsychotics, work by changing dopamine levels, a brain chemical that affects mood, motivation, and thinking [according to Jelena Kunovac, MD, a board-certified psychiatrist and adjunct assistant professor at the University of Nevada, Las Vegas, in the Department of Psychiatry]. Cobenfy takes a different approach by adjusting acetylcholine, another brain chemical that aids memory, learning and attention, she said. By focusing on acetylcholine instead of dopamine, Cobenfy may reduce schizophrenia symptoms while avoiding common side effects like weight gain, drowsiness and movement disorders, clinical trials suggest. These side effects often become so severe and unpleasant that, in some studies mirroring real-world challenges, many patients stopped treatment within 18 months of starting it.

In clinical trials, only 6% of patients stopped taking Cobenfy due to side effects, noted Dr. Samit Hirawat, chief medical officer at Bristol Myers Squibb. "That's a significant improvement over the 20-30% seen with older antipsychotic drugs," he added...

Schizophrenia is a mental health disorder that affects about 24 million people worldwide, or roughly one in 300 people, according to the World Health Organization.
"Studies for additional therapeutic uses, including the treatment of Alzheimer's disease and bipolar disorder, are also underway."

The world's oldest and largest cancer research association "found excessive levels of alcohol consumption increase the risk for six different types of cancer," reports CBS News: "Some of this is happening through chronic inflammation. We also know that alcohol changes the microbiome, so those are the bacteria that live in your gut, and that can also increase the risk," Dr. Céline Gounder, CBS News medical contributor and editor-at-large for public health at KFF Health News, recently said on "CBS Mornings."

But how much is too much when it comes to drinking? We asked experts what to know. "Excessive levels of alcohol" equates to about three or more drinks per day for women and four or more drinks per day for men, Gounder said... Other studies have shown, however, there is no "safe amount" of alcohol, Gounder said, particularly if you have underlying medical conditions. "If you don't drink, don't start drinking. If you do drink, really try to keep it within moderation," she said.

Dr. Amy Commander, medical director of the Mass General Cancer Center specializing in breast cancer, told CBS News alcohol is the third leading modifiable risk factor that can increase cancer risk after accounting for cigarette smoking and excess body weight. [Other factors include physical inactivity — and diet]. "There really isn't a safe amount of alcohol for consumption," she said. "In fact, it's best to not drink alcohol at all, but that is obviously hard for many people. So I think it's really important for individuals to just be mindful of their alcohol consumption and certainly drink less."
The article also includes an interesting statistic from the association's latest Cancer Progress Report: from 1991 to 2021 there's been a 33% reduction in overall cancer deaths in the U.S. That's 4.1 million lives saved — roughly 136,667 lives saved each year.

"So that is hopeful," Commander said, adding that when it comes to preventing cancer, alcohol is just "one piece of the puzzle."

An anonymous reader quotes a report from 404 Media: After a horseback riding accident left him paralyzed from the waist down in 2009, former jockey Michael Straight learned to walk again with the help of a $100,000 ReWalk Personal exoskeleton. Earlier this month, that exoskeleton broke because of a malfunctioning piece of wiring in an accompanying watch that makes the exoskeleton work. The manufacturer refused to fix it, saying the machine was now too old to be serviced, and Straight once again couldn't walk anymore. "After 371,091 steps my exoskeleton is being retired after 10 years of unbelievable physical therapy," Straight posted on Facebook on September 16. "The reasons [sic] why it has stopped is a pathetic excuse for a bad company to try and make more money. The reason it stopped is because of a battery in the watch I wear to operate the machine. I called thinking it was no big deal, yet I was told they stopped working on any machine that was 5 years or older. I find it very hard to believe after paying nearly $100,000 for the machine and training that a $20 battery for the watch is the reason I can't walk anymore?"

Straight's experience is a nightmare scenario that highlights what happens when companies decide to stop supporting their products and do not actively support independent repair. It's also what happens without the protection of right to repair legislation that requires manufacturers to make repair parts, guides, and tools available to the general public. Specifically, a connection wire became desoldered from the battery in a watch that connects to the exoskeleton: "It's not the actual battery, but it's the little green connection piece we need to be the right fit and that's been our problem," Straight posted on Facebook. Straight's personal exoskeleton was broken for two months, he said in a video on Facebook. He was eventually able to get the device fixed after attention from an article in the Paulick Report, a website about the horse industry, and a spot on local TV. "It took me two months, and I got no results," he said in the video. With social media and news attention, "it only took you all four days, and look at the results," he said earlier this week while standing in the exoskeleton. "This is the dystopian nightmare that we've kind of entered in, where the manufacturer perspective on products is that their responsibility completely ends when it hands it over to a customer. That's not good enough for a device like this, but it's also the same thing we see up and down with every single product," Nathan Proctor, head of citizen rights group US PIRG's right to repair project told 404 Media. "People need to be able to fix things, there needs to be a plan in place. A $100,000 product you can only use as long as the battery lasts, that's enraging. We should not have to tolerate a society where this happens."

"We have all this technology we release into the wild and it changes people's lives, but there's no long-term thinking. Manufacturers currently have no legal obligation to support the equipment indefinitely and there's no requirements that they publish sufficient documentation to allow others to do it," Proctor said. "We need to set minimum standards for documentation so that, even if a company goes bankrupt or falls off the face of the earth, a technician with sufficient knowledge can fix it."

An anonymous reader quotes a report from TechCrunch: Microsoft today revealed Correction, a service that attempts to automatically revise AI-generated text that's factually wrong. Correction first flags text that may be erroneous -- say, a summary of a company's quarterly earnings call that possibly has misattributed quotes -- then fact-checks it by comparing the text with a source of truth (e.g. uploaded transcripts). Correction, available as part of Microsoft's Azure AI Content Safety API (in preview for now), can be used with any text-generating AI model, including Meta's Llama and OpenAI's GPT-4o.

"Correction is powered by a new process of utilizing small language models and large language models to align outputs with grounding documents," a Microsoft spokesperson told TechCrunch. "We hope this new feature supports builders and users of generative AI in fields such as medicine, where application developers determine the accuracy of responses to be of significant importance." Experts caution that this tool doesn't address the root cause of hallucinations. "Microsoft's solution is a pair of cross-referencing, copy-editor-esque meta models designed to highlight and rewrite hallucinations," reports TechCrunch. "A classifier model looks for possibly incorrect, fabricated, or irrelevant snippets of AI-generated text (hallucinations). If it detects hallucinations, the classifier ropes in a second model, a language model, that tries to correct for the hallucinations in accordance with specified 'grounding documents.'"

Os Keyes, a PhD candidate at the University of Washington who studies the ethical impact of emerging tech, has doubts about this. "It might reduce some problems," they said, "But it's also going to generate new ones. After all, Correction's hallucination detection library is also presumably capable of hallucinating." Mike Cook, a research fellow at Queen Mary University specializing in AI, added that the tool threatens to compound the trust and explainability issues around AI. "Microsoft, like OpenAI and Google, have created this issue where models are being relied upon in scenarios where they are frequently wrong," he said. "What Microsoft is doing now is repeating the mistake at a higher level. Let's say this takes us from 90% safety to 99% safety -- the issue was never really in that 9%. It's always going to be in the 1% of mistakes we're not yet detecting."

Friday America's Federal Trade Commission brought action against three companies for "anticompetitive and unfair" practices "that have artificially inflated the list price of insulin."

For years, many of the millions of Americans who need insulin to survive "have been forced to pay exorbitant prices for a product that's inexpensive to make," writes NPR. "Now, the federal government is targeting one part of the system behind high insulin prices." While out-of-pocket costs have gone down for many people to $35 a month, questions remain on how the drug became so expensive in the first place. In a new lawsuit filed Friday, the Federal Trade Commission said it's going after one link in the chain: pharmacy benefit managers. The FTC brought action against the top pharmacy benefit managers (PBMs) — CVS Health's Caremark Rx, Cigna's Express Scripts, and United Health Group's OptumRx — saying the companies created a "perverse drug rebate system" that artificially inflates the cost of insulin. If the suit is successful, it could further drive down costs for patients at the pharmacy counter.

PBMs are essentially the middlemen between drug manufacturers and insurance providers. Their job is to reduce drug prices. But the process is complex and opaque, and critics say they're actually driving prices up for patients. The FTC said a big issue is that PBMs' revenue is tied to rebates and fees — which are based on a percentage of a drug's list price. Essentially, in the case of insulin, when the drug costed more, it generated higher rebates and fees for PBMs. "Even when lower list price insulins became available that could have been more affordable for vulnerable patients, the PBMs systemically excluded them in favor of high list price, highly rebated insulin products," the FTC said in a press release on Friday.

The three PBMs named in the FTC lawsuit make up about 80% of the market. According to the suit, the PBMs collected billions of dollars in rebates and fees while insulin became increasingly unaffordable. Over the last two decades, the cost of the lifesaving drug shot up 600% — forcing many Americans with diabetes to ration their medication and jeopardize their health. In 2019, one 1 of 4 insulin patients was unable to afford their medication, according to the FTC. Some people have died.
The FTC's statement says the companies "have abused their economic power by rigging pharmaceutical supply chain competition in their favor, forcing patients to pay more for life-saving medication... While PBM respondents collected billions in rebates and associated fees according to the complaint, by 2019 one out of every four insulin patients was unable to afford their medication..."

"[A]ll drug manufacturers should be on notice that their participation in the type of conduct challenged here raises serious concerns, and that the Bureau of Competition may recommend suing drug manufacturers in any future enforcement actions."

An anonymous reader quotes a report from CBC News: Inside a bustling unit at St. Michael's Hospital in downtown Toronto, one of Shirley Bell's patients was suffering from a cat bite and a fever, but otherwise appeared fine -- until an alert from an AI-based early warning system showed he was sicker than he seemed. While the nursing team usually checked blood work around noon, the technology flagged incoming results several hours beforehand. That warning showed the patient's white blood cell count was "really, really high," recalled Bell, the clinical nurse educator for the hospital's general medicine program. The cause turned out to be cellulitis, a bacterial skin infection. Without prompt treatment, it can lead to extensive tissue damage, amputations and even death. Bell said the patient was given antibiotics quickly to avoid those worst-case scenarios, in large part thanks to the team's in-house AI technology, dubbed Chartwatch. "There's lots and lots of other scenarios where patients' conditions are flagged earlier, and the nurse is alerted earlier, and interventions are put in earlier," she said. "It's not replacing the nurse at the bedside; it's actually enhancing your nursing care."

A year-and-a-half-long study on Chartwatch, published Monday in the Canadian Medical Association Journal, found that use of the AI system led to a striking 26 percent drop in the number of unexpected deaths among hospitalized patients. The research team looked at more than 13,000 admissions to St. Michael's general internal medicine ward -- an 84-bed unit caring for some of the hospital's most complex patients -- to compare the impact of the tool among that patient population to thousands of admissions into other subspecialty units. "At the same time period in the other units in our hospital that were not using Chartwatch, we did not see a change in these unexpected deaths," said lead author Dr. Amol Verma, a clinician-scientist at St. Michael's, one of three Unity Health Toronto hospital network sites, and Temerty professor of AI research and education in medicine at University of Toronto. "That was a promising sign."

The Unity Health AI team started developing Chartwatch back in 2017, based on suggestions from staff that predicting deaths or serious illness could be key areas where machine learning could make a positive difference. The technology underwent several years of rigorous development and testing before it was deployed in October 2020, Verma said. Dr. Amol Verma, a clinician-scientist at St. Michael's Hospital who helped lead the creation and testing of CHARTwatch, stands at a computer. "Chartwatch measures about 100 inputs from [a patient's] medical record that are currently routinely gathered in the process of delivering care," he explained. "So a patient's vital signs, their heart rate, their blood pressure ... all of the lab test results that are done every day." Working in the background alongside clinical teams, the tool monitors any changes in someone's medical record "and makes a dynamic prediction every hour about whether that patient is likely to deteriorate in the future," Verma told CBC News.

Neuralink said on Tuesday it has received the FDA's "breakthrough device" designation for its experimental implant aimed at restoring vision. Called Blindsight, the device "will enable even those who have lost both eyes and their optic nerve to see," said Neuralink founder Elon Musk. Reuters reports: The FDA's breakthrough tag is given to certain medical devices that provide treatment or diagnosis of life-threatening conditions. It is aimed at speeding up development and review of devices currently under development. Neuralink did not immediately respond to a request seeking details about when it expects the Blindsight device to move into human trials.

An anonymous reader quotes a report from NBC News: Scientists in Brazil found microplastics in the brain tissue of cadavers, according to a new study published Monday in the journal JAMA Network Open. Mounting research over the last few years has found microplastics in nearly every organ in the body, as well as in the bloodstream and in plaque that clogs arteries. Whether these ubiquitous pollutants can reach the human brain has been a primary concern for scientists. The latest research looked at a part of the brain called the olfactory bulb, which processes information about smell. Humans have two olfactory bulbs, one above each nasal cavity. Connecting the olfactory bulb and the nasal cavity is the olfactory nerve.

Some researchers worry the olfactory pathway may also be an entry point for microplastics getting into the brain, beyond the olfactory bulb. "Previous studies in humans and animals have shown that air pollution reaches the brain, and that particles have been found in the olfactory bulb, which is why we think the olfactory bulb is probably one of the first points for microplastics to reach the brain," said lead study author Dr. Thais Mauad, an associate professor of pathology at the University of Sao Paulo Medical School in Brazil.

Mauad and her team took samples of olfactory bulb tissue from 15 cadavers of people who died between the ages of 33 and 100. Samples from eight of the cadavers contained microplastics -- tiny bits of plastic that ranged from 5.5 micrometers to 26.4 micrometers in size. In total, the researchers found 16 plastic fibers and particles in the tissues. The smallest were slimmer than the diameter of a human red blood cell, which measures about 8 micrometers. The most common type of plastic they found was polypropylene, followed by polyamide, nylon and polyethylene vinyl acetate. "The nose is a major point of defense to keep particles and dust out of the lungs," Campen wrote in an email. "So seeing some plastics in the olfactory system, especially given how they are being found everywhere else in the body, is completely expected." [...] "There is evidence that very small airborne particles can move to the brain via the olfactory bulb, but this is not known to be a major route of trafficking material to the brain," Campen said. Campen notes it's more likely that nanoplastics enter the brain through the bloodstream, which picks up plastic bits from the lungs or digestive tract, rather than the olfactory bulb. "However, it's extremely difficult for particles, even those in pharmaceuticals, to enter the brain through the blood," notes NBC News. "That's because the brain is surrounded by a semipermeable membrane called the blood-brain barrier."

Retraction Watch: A Nobel prize-winning genetics researcher has retracted two more papers, bringing his total to 13. Gregg Semenza, a professor of genetic medicine and director of the vascular program at Johns Hopkins' Institute for Cell Engineering in Baltimore, shared the 2019 Nobel prize in physiology or medicine for "discoveries of how cells sense and adapt to oxygen availability." Since pseudonymous sleuth Claire Francis and others began using PubPeer to point out potential duplicated or manipulated images in Semenza's work in 2019, the researcher has retracted 12 papers. A previous retraction from 2011 for a paper co-authored with Naoki Mori -- who with 31 retractions sits at No. 25 on our leaderboard -- brings the total to 13.

More details on that report about NASA from the Washington Post: NASA is 66 years old and feeling its age. Brilliant engineers are retiring. Others have fled to higher-paying jobs in the private space industry. The buildings are old, their maintenance deferred. The Apollo era, with its huge taxpayer investment, is a distant memory. The agency now pursues complex missions on inadequate budgets. This may be an unsustainable path for NASA, one that imperils long-term success. That is the conclusion of a sweeping report, titled "NASA at a Crossroads," written by a committee of aerospace experts and published Tuesday by the National Academies of Sciences, Engineering and Medicine. The report suggests that NASA prioritizes near-term missions and fails to think strategically. In other words, the space agency isn't sufficiently focused on the future.

NASA's intense focus on current missions is understandable, considering the unforgiving nature of space operations, but "one tends to neglect the probably less glamorous thing that will determine the success in the future," the report's lead author, Norman Augustine, a retired Lockheed Martin chief executive, said Tuesday. He said one solution for NASA's problems is more funding from Congress. But that may be hard to come by, in which case, he said, the agency needs to consider canceling or delaying costly missions to invest in more mundane but strategically important institutional needs, such as technology development and workforce training. Augustine said he is concerned that NASA could lose in-house expertise if it relies too heavily on the private industry for newly emerging technologies. "It will have trouble hiring innovative, creative engineers. Innovative, creative engineers don't want to have a job that consists of overseeing other people's work," he said...

The report is hardly a blistering screed. The tone is parental. It praises the agency — with a budget of about $25 billion — for its triumphs while urging more prudent decision-making and long-term strategizing.

NASA pursues spectacular missions. It has sent swarms of robotic probes across the solar system and even into interstellar space. Astronauts have continuously been in orbit for more than two decades. The most ambitious program, Artemis, aims to put astronauts back on the moon in a few short years. And long-term, NASA hopes to put astronauts on Mars. But a truism in the industry is that space is hard. The new report contends that NASA has a mismatch between its ambitions and its budget, and needs to pay attention to fundamentals such as fixing its aging infrastructure and retaining in-house talent. NASA's overall physical infrastructure is already well beyond its design life, and this fraction continues to grow," the report states.
NASA Administrator Bill Nelson said the report "aligns with our current efforts to ensure we have the infrastructure, workforce, and technology that NASA needs for the decades ahead," according to the article.

Nelson added that the agency "will continue to work diligently to address the committee's recommendations."

An anonymous reader quotes a report from CBC News: Stranded astronauts Butch Wilmore and Suni Williams said Friday it was hard to watch their Boeing capsule return to Earth without them. It was their first public comments since last week's return of the Boeing Starliner capsule that took them to the International Space Station in June. They remained behind after NASA determined the problem-plagued capsule posed too much risk for them to ride back in. "That's how it goes in this business," said Williams, adding that "you have to turn the page and look at the next opportunity."

Wilmore and Williams are now full-fledged station crew members, chipping in on routine maintenance and experiments. They, along with seven others on board, welcomed a Soyuz spacecraft carrying two Russians and an American earlier this week, temporarily raising the station population to 12, a near record. NASA astronauts Butch Wilmore and Suni Williams spoke to the press on Friday for the first time since their Boeing Starliner capsule returned to Earth without them. The two, who have been on the International Space Station since June 6, said they are taking the mission's unexpected extension into 2025 in stride -- even if it means they've had to change their voting plans. The transition to station life was "not that hard" since both had previous stints there, said Williams, who will soon take over as station commander. "This is my happy place. I love being up here in space," she said.

The two Starliner test pilots -- both retired U.S. navy captains and longtime NASA astronauts — will stay at the orbiting laboratory until late February. They have to wait for a SpaceX capsule to bring them back. That spacecraft is due to launch later this month with a reduced crew of two, with two empty seats for Wilmore and Williams for the return leg. The duo said they appreciated all the prayers and well wishes from strangers back home. Wilmore said he will miss out on family milestones such as being around for his youngest daughter's final year of high school. The astronauts, who prepared for eight days in space, will now be up there for eight months, which could have a greater impact on the body. "It is a bit of a change from a sprint to a marathon," said Dr. Adam Sirek of the Canadian Society of Aerospace Medicine.

Researchers have discovered that people with depression have an expanded brain network, specifically the frontostriatal salience network, which is 73% larger compared to healthy individuals. "It's taking up more real estate on the brain surface than we see is typical in healthy controls," said Dr Charles Lynch, a co-author of the research, from Weill Cornell Medicine in New York. He added that expansion meant the size of other -- often neighboring -- brain networks were smaller. The Guardian reports: Writing in the journal Nature, Lynch and colleagues report how they used precision functional mapping, a new approach to brain imaging that analyses a host of fMRI (functional MRI) scans from each individual. The team applied this method to 141 people with depression and 37 people without it, enabling them to measure accurately the size of each participant's brain networks. They then took the average size for each group. They found that a part of the brain called the frontostriatal salience network was expanded by 73% on average in participants with depression compared with healthy controls.

These findings were supported by an analysis of single brain scans previously collected from 932 healthy people and 299 with depression. The team said the size of this brain network in people with depression did not change with time, mood or transcranial magnetic stimulation treatment. However, brain signals between different parts of the network became less synchronised when participants had certain symptoms of depression, with these changes also associated with the severity of future symptoms. The team added that an analysis of brain scans from 57 children who went on to develop depression as adolescents revealed this brain network was expanded years before their symptoms developed, while it was also expanded in adults with late onset depression.

The researchers said this suggested an expanded brain network could be a risk factor for developing depression, rather than a consequence of the condition. However, they said it was unclear to what extent this enlarged network was the result of genetics or experiences, and whether the association with depression arose from this expansion or from other brain networks consequently being smaller. The team added that their results could offer a way to explore whether certain people may be at increased risk of developing depression, and could help develop personalised treatments.

An anonymous reader quotes a report from 404 Media, written by Jason Koebler: I've been videochatting with Mixael Swan Laufer for about 30 minutes about an exciting discovery when he points out that to date, the best way he's been able to bring attention to his organization is "the old school method of me performing a bunch of federal felonies on stage in front of a bunch of people." I stop him and ask: "In this case, what are the felonies?" "Well, the list is pretty long," he said. Laufer is the chief spokesperson of Four Thieves Vinegar Collective, an anarchist collective that has spent the last few years teaching people how to make DIY versions of expensive pharmaceuticals at a tiny fraction of the cost.

Four Thieves Vinegar Collective call what they do "right to repair for your body." Laufer has become well known for handing out DIY pills and medicines at hacking conferences, which include, for example, courses of the abortion drug misoprostol that can be manufactured for 89 cents (normal cost: $160) and which has become increasingly difficult to obtain in some states following the Supreme Court decision in Dobbs. In our call, Laufer had just explained that Four Thieves' had made some miscalculations as part of its latest project, to create instructions for replicating sofosbuvir (Sovaldi), a miracle drug that cures hepatitis C, which he planned to explain and reveal at the DEF CON hacking conference. Unlike many other drugs that treat viruses, Sovaldi does not suppress hepatitis C, a virus that kills roughly 250,000 people around the world each year. It cures it. [...]

Crucially, unlike other medical freedom organizations, Four Thieves isn't suggesting people treat COVID with Ivermectin, isn't shilling random supplements, and doesn't have any sort of commercial arm at all. Instead, they are helping people to make their own, identical pirated versions of proven and tested pharmaceuticals by taking the precursor ingredients and performing the chemical reactions to make the medication themselves. "We don't invent anything, really," Laufer said. "We take things that are on the shelf and hijack them. We like to take something established, and be like 'This works, but you can't get it.' Well, here's a way to get it." A slide at his talk reads "Isn't this illegal? Yeah. Grow up." Four Thieves has developed a suite of open-source tools to help achieve its goal. The core tool, Chemhacktica, is a software platform that uses machine learning to map chemical pathways for synthesizing desired molecules. It suggests potential chemical reactions, identifies precursor materials, and checks their availability for purchase.

The other is Microlab, an open-source controlled lab reactor built from affordable, off-the-shelf components costing between $300 and $500. It uses Chemhacktica's suggested pathways to create medications, and detailed instructions for building and operating the Microlab are provided. Additionally, the company developed a drag-and-drop recipe system called Apothecarium that generates executable files for the Microlab, offering step-by-step guidance on producing specific medications.

Laufer told 404 Media: "I am of the firm belief that we are hitting a watershed where economics and morality are coming to a head, like, 'Look: intellectual property law is based off some ideas that came out of 1400s Venice. They're not applicable and they're being abused and people are dying every day because of it, and it's not OK.'"

Further reading: Meet the Anarchists Making Their Own Medicine (Motherboard; 2018)

An anonymous Slashdot reader shared this report from NBC News: A new approach to a routine blood test could predict a person's 30-year risk of heart disease, research published Saturday in the New England Journal of Medicine found.

Doctors have long assessed their patients' risk for cardiovascular disease by using a blood test to look at cholesterol levels, focusing particularly on LDL or "bad" cholesterol. But limiting blood testing to just cholesterol misses important — and usually silent — risk factors, experts say... Lead study author Dr. Paul Ridker, director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital in Boston and his team found that in addition to LDL cholesterol, two other markers — a type of fat in the blood called lipoprotein (a), or Lp(a), and an indicator of inflammation — are important predictors of a person's risk of heart attack, stroke and coronary heart disease...

In the study, the researchers analyzed data from nearly 30,000 U.S. women who were part of the Women's Health Study. On average, the women were 55 years old when they enrolled in the years 1992 through 1995. About 13% — roughly 3,600 participants — had either a heart attack or stroke, had surgery to fix a narrowed or blocked artery, or died from heart disease over the 30-year follow-up period... All of the women had blood tests done at the beginning of the study to measure their LDL cholesterol, Lp(a) and C-reactive protein levels, a marker of inflammation in the body. These measurements, individually as well as together, appeared to predict a woman's heart health over the next three decades, the study found.

Women with the highest levels of LDL cholesterol had a 36% higher risk for heart disease compared with those with the lowest levels. The highest levels of Lp(a) indicated a 33% elevated risk, and those with the highest levels of CRP were 70% more at risk for heart disease. When the three were looked at together, women who had the highest levels were 1.5 times more likely to have a stroke and over three times more likely to develop coronary heart disease over the next 30 years compared with women with the lowest levels.

All of the markers have been individually linked to higher risk of heart disease, but "all three represent different biological processes. They tell us why someone is actually at risk," Ridker said.